Top Markets
Coin of the day
Mustang Bio, Inc. Mustang Bio, Inc.

Mustang Bio, Inc.

MBIO
Rang in Aktien #35075
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on... Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Aktienkurs
$0.594
Zuletzt synchronisiert: 2026-08-14
Marktkapitalisierung
$4.50M
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
-66.44%
Land
US
Handel Mustang Bio, Inc. (MBIO)

Kategorie

Dividendenrendite-Verlauf für Mustang Bio, Inc. (MBIO)
Dividendenrendite (TTM) von Mustang Bio, Inc. (Aktienkürzel: MBIO) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Mustang Bio, Inc. (MBIO) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber